A Cross-Sectional Pilot Study on Pharmacovigilance to Improve the Drug Safety in Bangladesh

Author:

Akter Hossain Md.1ORCID,Shah Amran Md.2ORCID

Affiliation:

1. Directorate General of Drug Administration, Mohakhali, Dhaka, Bangladesh.

2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh.

Abstract

The monitoring of drug safety is a crucial element for the effective use of medicines to maintain high-quality medical care. The aim of this study was to analyze the adverse drug reactions (ADRs) as well as improve drug safety through pharmacovigilance (PV) in Bangladesh. The research work was conducted on the basis of a questionnaire by taking interviews of targeted stakeholders including academicians, doctors, pharmacists, manufacturers of drugs and directorate general of drug administration (DGDA) personnel. The study was conducted on 496 participants at Dhaka Metropolitan Dhaka, Rajshahi and Khulna Divisions from July 2015 to June 2018. Outcomes showed that among the interviewed populations 23% were female and 77% were male. Among participants, 66.9% of the interviewee was postgraduate degree holders. 62.7% respondents were familiar with the word element PV and 37.3% were ignorant of it. The major problem of DGDA to spreading the knowledge of PV was less manpower (73.9%). Among the factors that must be stopped to avoid the ADRs were the unethical practice of the healthcare professionals (50%). The topmost prioritized component was an education for knowledge (71.4%). It was found that many of the facilities for adverse drug reaction monitoring (ADRM) were absent in Bangladesh. The manpower and strength of DGDA must be increased to perform adequate monitoring and control as per the need of the country. We recapitulate that more research and development programs on PV activities in the country to improve the quality healthcare services is needed.

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference19 articles.

1. WHO. WHO | Pharmacovigilance. WHO. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Published 2015. Accessed February 28, 2019.

2. Bégaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985;40(2):111-118. http://www.ncbi.nlm.nih.gov/pubmed/4002188. Accessed February 28, 2019.

3. WHO. WHO | The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). WHO. https://www.who.int/classifications/atcddd/en/. Published 2010. Accessed February 28, 2019.

4. Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ. Principles of Signal Detection in Pharmacovigilance. Drug Saf. 1997;16(6):355-365. doi:10.2165/00002018-199716060-00002.

5. Meyboom RHB, Gribnau FWJ, Hekster YA, de Koning GHP, Egberts ACG. Characteristics of Topics in Pharmacovigilance in The Netherlands†. Clin Drug Investig. 1996;12(4):207-219. doi:10.2165/00044011-199612040-00006.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3